The purpose of this paper is to assess the clinical effectiveness of Polybutine Compositium in the treatment of patients with the various gastrointestinal diseases. The total number of subjects was 51 patients (male; 25 cases, female: 26 cases). Among them 32 were treated with Polybutine Compositium (Drug A), and 19 with Trimebutine (Drug B). Polybutine Compositium or Trimebutine was administered at dose of 4 capsules daily for 15 days. Symptoms were scored before and after the study. And the results are as follows: 1) Initial symptoms were abdominal pain (100.0%), anorexia (98.0%), heartburn (94.1%), nausea (90. 2%), abdominal distension (84.3%), constipation (82.4%), vomiting (74.5%), flatulence (70.6%), diarrhea (51.0%), and malaise (43.1%). The effect rates (percent of cured and improved cases to total ones) of Polybutine Compositium on each symtpoms were malaise (100.0%), abdominal pain (96.9%), nausea (95.7%), constipation (92.6%), heartburn (90.0%), anorexia (87.5%), nausea (86.2%), abdominal distension (82.1%), diarrhea (75.0%), and flatulence (72.7%). 2) Symptom score was significantly decreased in patients with Polybutine Compositium than those with Trimebutine (p<0.01), indicating a significant Polybutine Compositium effect compared to Trimebutine. 3) No definite side effect of Polybutine Compositium was found at dose of 4 capsules daily. In conclusion, Polybutine Compositium is an effective agent in controlling the symptom complex of various gastrointestinal diseases.